Darmstadt, Germany

Gudrun Birk

This inventor holds 2 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignee: Merck Patent Gmbh. Active years: 2020-2021.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.9

ph-index = 1


Company Filing History:


Years Active: 2020-2021

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Gudrun Birk: Innovator in Pharmaceutical Formulations

Introduction

Gudrun Birk is a prominent inventor based in Darmstadt, Germany. She has made significant contributions to the field of pharmaceutical formulations, holding 2 patents that showcase her innovative spirit and dedication to advancing medical science.

Latest Patents

Her latest patents include the invention of compacted glycine granules, where at least 75% of the granules have a particle size of above 0.7 mm. This invention relates to a process for the preparation and use of such granules. Additionally, she has developed novel pharmaceutical formulations that provide controlled, delayed release of active ingredients. This formulation is particularly useful for treating diseases that require such delayed release, including hypertension and asthmatic conditions.

Career Highlights

Gudrun Birk is currently associated with Merck Patent GmbH, where she continues to work on innovative solutions in the pharmaceutical industry. Her expertise and research have positioned her as a key figure in her field.

Collaborations

Throughout her career, she has collaborated with notable colleagues, including Dieter Lubda and Guenter Moddelmog, contributing to a dynamic and innovative work environment.

Conclusion

Gudrun Birk's contributions to pharmaceutical formulations highlight her role as a leading inventor in the industry. Her work continues to impact the treatment of various medical conditions, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…